Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice

@article{FRACPNCKaralusMBCh1995Roxithromycin1M,
  title={Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice},
  author={B. FRACPN.C.KaralusM.B.Ch. and B. FRACPJ.E.GarrettM.B.Ch. and B. FRACPS.D.R.LangM.B.Ch. and B. FRCPAR.A.LengM.B.Ch. and S. G.N.KostalasM.B.B. and D. R.T.M.CursonsPh. and B. B.H.B.B.C.CooperM.B.Ch. and N. C.J.RyanN.Z.R.},
  journal={Infection},
  year={1995},
  volume={23},
  pages={S15-S20}
}
Two hundred and forty-two patients over 16 years of age with community-acquired lower respiratory tract infection (LRTI), matched for age and sex, were randomised to receive either roxithromycin 150 mg b.i.d. or amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for 7 days, with a further 7 days if insufficient response was seen. Clinical efficacy at 7 days was 69% for roxithromycin and 56% for amoxycillin/clavulanic acid (p=0.05) and at study end it was 91% for both antibiotics. There were fewer… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Infections caused by Chlamydia pneumoniae strain TWAR.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 1992
View 1 Excerpt

Bacteriological and clinical evaluation of roxithromycin in pneumonia

A. Saito
JAMA Supp. 6 (SEA) • 1990

Similar Papers

Loading similar papers…